In Rare Move, FDA Panel Gives Support to Controversial ALS Drug in Second Review

THURSDAY, Sept. 8, 2022 -- In a rare second review, a U.S. Food and Drug Administration panel on Wednesday recommended approval for an experimental drug for amyotrophic lateral sclerosis (ALS). The FDA is not obligated to follow its advisers ' ...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news